Prime Medicine
Gene editing company advancing prime editing technology to develop a new class of genetic medicines capable of making virtually any type of edit to the genome with high precision.
Website
https://primemedicine.comLocation
Cambridge, Massachusetts, USA
Founded
2019
Investors
3
Categories
biotech, gene-editing, prime-editing, therapeutics
Notes
Prime Medicine is a leading gene editing company advancing prime editing, a revolutionary gene editing technology that can make virtually any type of DNA edit with high precision. Prime editing was developed at the Broad Institute by Dr. David Liu and licensed to Prime Medicine.
Unlike traditional CRISPR, prime editing can perform precise insertions, deletions, and all 12 types of point mutations without requiring double-strand breaks or donor DNA templates, offering a potentially safer and more versatile approach to genetic medicines.
Team
- Keith Gottesdiener, M.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/keithgottesdiener
- David Liu, Ph.D. - Founder & Scientific Advisor (Harvard/Broad Institute)
Additional Research Findings
- Founded in 2019 in Cambridge, Massachusetts
- Listed on NASDAQ (ticker: PRME)
- Investors include F-Prime Capital, ARCH Venture Partners, CE-Ventures
- Exclusive license to prime editing technology from Broad Institute
- Technology enables precise genome editing without double-strand breaks
- Multiple therapeutic programs across genetic diseases
- Lead programs in liver and eye diseases
- Considered next-generation gene editing approach
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| CE-Ventures (Crescent Enterprises) | Sharjah, UAE | generalist | seedseries-a+3 | 4 |
| F-Prime Capital | Cambridge, USA | biotech-focused | seedseries-a+2 | 2 |
| ARCH Venture Partners | Chicago, USA | biotech-focused | seedseries-a+3 | 6 |